Melanoma

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology…

11 months ago

DermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting

DermaSensor’s Device with FDA Breakthrough Designation Demonstrated 96.2% Sensitivity for Detecting Melanoma in Patients Aged 65 and OlderMIAMI--(BUSINESS WIRE)--DermaSensor Inc.,…

12 months ago

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

SHANGHAI, China, July 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

12 months ago

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC)…

12 months ago

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 2:00 PM ETBERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- Panavance…

12 months ago

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for…

12 months ago

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023…

12 months ago

Advanced Health Intelligence Ltd Announces Implementation of ADS Ratio Change

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (“Advanced Health Intelligence”, “AHI” or the “Company”)…

12 months ago

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migrationGP-2250…

12 months ago

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial…

12 months ago